Except it is not. Not yet. Not for enrollment.

At many institutions--particularly academic medical centers and hospital-based research programs--IRB approval is necessary but not sufficient for a study to begin. Between that IRB approval letter and the moment the first participant can be consented, there may be five, six, or even eight additional approvals, notifications, and signoffs required. A pharmacy and therapeutics committee must review the investigational product handling plan. A radiation safety committee must authorize any protocol-required imaging that involves ionizing radiation. A biosafety committee must approve procedures involving recombinant DNA or select agents. The department chair must sign off. The research compliance office must confirm that the Medicare coverage analysis is complete. And all of these committees operate on their own schedules--monthly meetings, quarterly reviews, administrative queues that do not know or care about the sponsor's activation timeline.

I have seen coordinators lose six to eight weeks at this stage. Not because anything was wrong with their submissions, but because they approached these approvals sequentially--waiting for one to complete before initiating the next--when several could have been running in parallel from the moment the protocol was available. That is, in my view, the single most avoidable delay in the entire start-up process. And it is entirely within the coordinator's control to prevent it.

This lesson maps the regulatory terrain between IRB approval and enrollment authorization. You will learn what notifications and approvals are required, which committees you must satisfy, how coverage analysis works, and--most importantly--how to orchestrate all of these moving parts so they converge on the earliest possible activation date rather than stringing out in a costly, unnecessary sequence.

Except it is not. Not yet. Not for enrollment.

At many institutions--particularly academic medical centers and hospital-based research programs--IRB approval is necessary but not sufficient for a study to begin. Between that IRB approval letter and the moment the first participant can be consented, there may be five, six, or even eight additional approvals, notifications, and signoffs required. A pharmacy and therapeutics committee must review the investigational product handling plan. A radiation safety committee must authorize any protocol-required imaging that involves ionizing radiation. A biosafety committee must approve procedures involving recombinant DNA or select agents. The department chair must sign off. The research compliance office must confirm that the Medicare coverage analysis is complete. And all of these committees operate on their own schedules--monthly meetings, quarterly reviews, administrative queues that do not know or care about the sponsor's activation timeline.

I have seen coordinators lose six to eight weeks at this stage. Not because anything was wrong with their submissions, but because they approached these approvals sequentially--waiting for one to complete before initiating the next--when several could have been running in parallel from the moment the protocol was available. That is, in my view, the single most avoidable delay in the entire start-up process. And it is entirely within the coordinator's control to prevent it.

This lesson maps the regulatory terrain between IRB approval and enrollment authorization. You will learn what notifications and approvals are required, which committees you must satisfy, how coverage analysis works, and--most importantly--how to orchestrate all of these moving parts so they converge on the earliest possible activation date rather than stringing out in a costly, unnecessary sequence.